Tag Archives: NASDAQ:IMV

H.C. Wainwright Reaffirms Their Buy Rating on IMV Inc. (IMV)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on IMV Inc. (IMV – Research Report), with a price target of $11.50. The company’s shares closed last Monday at $2.63, close to its 52-week low

IMV Inc. (IMV) Receives a Buy from B.Riley FBR

B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on IMV Inc. (IMV – Research Report) today and set a price target of $11. The company’s shares closed on Friday at $2.40, close to its 52-week low of $2.25. Mamtani

IMV Inc. (IMV) Gets a Buy Rating from H.C. Wainwright

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on IMV Inc. (IMV – Research Report), with a price target of $11.50. The company’s shares opened today at $2.25, equals to its 52-week low of

H.C. Wainwright Keeps a Buy Rating on IMV Inc. (IMV)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on IMV Inc. (IMV – Research Report), with a price target of $11.50. The company’s shares closed yesterday at $4. Pantginis wrote: “Valuation and risks to

IMV Inc. (IMV) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on IMV Inc. (IMV – Research Report) today and set a price target of $11.50. The company’s shares closed on Friday at $4.33. Pantginis commented: “Valuation and risks to price target

Analysts Are Bullish on These Healthcare Stocks: IMV Inc. (IMV), Biogen Inc (BIIB)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on IMV Inc. (IMV – Research Report) and Biogen Inc (BIIB – Research Report) with bullish sentiments. IMV Inc. (IMV) In a report